8-K: Aditxt Subsidiary Pearsanta Acquires Adductomics Platform for Early Cancer Prevention

Aditxt's subsidiary, Pearsanta, acquires the Adductomics platform to enhance early cancer detection and prevention capabilities.

Summary

• Aditxt, Inc. hosted a corporate update on March 28, 2025, focusing on Pearsanta's acquisition of the Adductomics platform.
• The Adductomics platform is a technology designed to assess early DNA changes that may lead to mutations associated with cancer and other illnesses.
• Pearsanta aims to shift the diagnostic timeline forward to detect diseases earlier, when treatments can be more effective.
• The company is pursuing an IPO to raise capital for advancing Pearsanta's mission.
• The first test in cancer will be the prostate cancer test using mitochondrial DNA biomarkers.
• The Adductomics technology detects harmful chemical modifications to DNA caused by carcinogens and environmental factors.
• The company anticipates launching tests and fully commercializing its platform after the IPO later this year.
• Pearsanta is in dialogue with partners covering over 46 countries outside the US for global distribution.

Sentiment

Score: 7

Explanation: The document conveys a positive outlook due to the acquisition of a promising technology and plans for an IPO, but it also acknowledges the challenges of a small company and market conditions.

Positives

• Acquisition of the Adductomics platform strengthens Pearsanta's position in early disease detection.
• The Adductomics platform complements the existing Mitomic platform, providing a multidimensional view of disease.
• Pearsanta is pursuing an IPO to secure capital for accelerating development and commercialization.
• The company has a clear product roadmap, with the first cancer test focused on prostate cancer.
• Pearsanta is establishing partnerships for global distribution of its tests.
• The Adductomics platform does not collect genetic information that can identify a person, addressing privacy concerns.

Negatives

• The Adductomics platform is not yet commercial-ready and requires further development and validation.
• The company is a small company and things of that nature require financing.
• The market has been challenging for many companies that can deliver on a big promise.

Risks

• The company's forward-looking statements are subject to risks, including the failure to complete proposed transactions and realize anticipated benefits.
• The company's assumptions may prove incorrect, and actual results could differ materially from those implied by forward-looking statements.
• The company faces risks and uncertainties indicated in its public filings with the SEC.
• The market has been challenging for many companies that can deliver on a big promise.

Future Outlook

Pearsanta is pursuing an IPO later this year to raise capital for accelerating development and commercialization of its early disease detection platform, with plans for global distribution.

Management Comments

• Amro Albanna: 'The best treatment for cancer is not to get it in the first place, and the second-best treatment for cancer is to catch it early.'
• Chris Mitton: 'At Pearsanta, our mission is to shift the diagnostic timeline forward to detect disease earlier when treatments and interventions can be more effective.'
• Roger Giese: 'Nothing beats primary prevention for cancer. You catch it at a risk stage.'
• Shahrokh Shabahang: 'Having this information at hand is really critical, and what really interested me about this technology is that we have now a potential to evaluate dynamic changes that happen over time.'

Industry Context

The announcement highlights the growing focus on early disease detection and personalized medicine in the healthcare industry, with companies like Pearsanta leveraging innovative technologies to address unmet needs in cancer prevention and diagnostics.

Comparison to Industry Standards

• 23andMe also test DNA, and so in that sense, were in the same testing world.
• 23andMe collects genetic information about people, but Pearsanta does not collect genetic information, we dont collect DNA sequence information, so theres no information that we collect that can in any way identify a person.

Stakeholder Impact

• Shareholders may benefit from the potential growth and value creation of Pearsanta.
• Employees will have opportunities to contribute to the development and commercialization of innovative technologies.
• Customers may gain access to earlier and more effective disease detection and prevention tools.
• The company is in dialogue with partners covering over 46 countries outside the US for global distribution.

Next Steps

• Pearsanta will continue developing and validating the Adductomics platform.
• Pearsanta will pursue an IPO later this year.
• The company will launch its first cancer test for prostate cancer.
• Pearsanta will expand its reach globally through partnerships.
• Aditxt will provide an update after the [inaudible 00:26:29] case is filed.

Key Dates

Keywords

Aditxt, Pearsanta, Adductomics, Early Disease Detection, Cancer Prevention, IPO, Mitochondrial DNA, Diagnostics, Biomarkers, Healthcare